Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States

Authors Quock TP, Yan T, Tieu R, D'Souza A, Broder MS

Received 28 February 2019

Accepted for publication 23 June 2019

Published 15 July 2019 Volume 2019:11 Pages 431—439


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Samer Hamidi

Tiffany P Quock,1 Tingjian Yan,2 Ryan Tieu,2 Anita D’Souza,3 Michael S Broder2

1Medical Affairs, Prothena Biosciences Inc, South San Francisco, CA, USA; 2Health Services Research, Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA; 3Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

Purpose: Cardiac dysfunction is common in amyloid light-chain (AL) amyloidosis, a rare disease caused by extracellular deposition of misfolded immunoglobulin light chains. This study aimed to examine economic/clinical disease burden in hospitalized cardiac amyloidosis patients.
Patients and methods: Cardiac amyloidosis patients ≥18 years old hospitalized between 2014 and 2016 were identified in claims if they had ≥1 inpatient claim consistent with amyloidosis and evidence of cardiac dysfunction. Descriptive statistics were reported.
Results: 3239 cardiac amyloidosis patients [1795 (55.4%) with concurrent renal disease] were identified. Mean (SD) length of stay was 8.3 (11.1) days. 25.2% were admitted to the intensive care unit. Mean overall hospitalization costs were USD$20,584. In-hospital mortality was 9.0% overall. 16.8% were readmitted within 30 days, with 11.2% dying in-hospital and a mean readmission cost of USD$18,536.
Conclusion: Hospitalization for cardiac amyloidosis is costly, with high rates of readmission and mortality. Opportunities exist to improve care.

Keywords: cardiac amyloidosis, hospitalization, burden of illness, cost

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]